STAT+: Q&A: James ‘Jim’ Mullen on Editas, why he took the job as CEO, and his vision for the future
On Monday, Editas Medicines announced that veteran biopharma executive James “Jim” Mullen was expanding his role with the gene-editing biotech, taking over as the new CEO while continuing as the company’s chairman — a role he’s held since March 2018.
Mullen replaces Cynthia Collins, who became Editas’ CEO in August 2019.
Continue to STAT+ to read the full story…
